However, considering that the CyclinD1-CDK4/6-Rb pathway is downstream of the EGFR signaling pathway, it is likely that this cell cycle pathway, which involves CDKN2B and RB1, plays an important role in lung cancer progression and/or therapeutic resistance in patients with EGFR active mutation. Here, RB1 is linked to lung cancer.